Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT03914612
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:29:07.231460+00:00
Published At
2025-03-18T00:00:00+00:00
Record Updated At
2026-04-21
Results Posted At
2025-03-18
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Endometrial Clear Cell Adenocarcinoma", "Endometrial Dedifferentiated Carcinoma", "Endometrial Endometrioid Adenocarcinoma", "Endometrial Mixed Cell Adenocarcinoma", "Endometrial Serous Adenocarcinoma", "Endometrial Undifferentiated Carcinoma", "Recurrent Endometrial Adenocarcinoma", "Recurrent Endometrial Carcinoma", "Recurrent Endometrial Clear Cell Adenocarcinoma", "Recurrent Endometrial Dedifferentiated Carcinoma", "Recurrent Endometrial Endometrioid Adenocarcinoma", "Recurrent Endometrial Mixed Cell Adenocarcinoma", "Recurrent Endometrial Serous Adenocarcinoma", "Recurrent Endometrial Undifferentiated Carcinoma", "Stage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8", "Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2026-04-21"
protocolSection.identificationModule.nctId
"NCT03914612"
protocolSection.identificationModule.officialTitle
"A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer"
protocolSection.statusModule.overallStatus
"ACTIVE_NOT_RECRUITING"
protocolSection.designModule.phases
["PHASE3"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
"2025-03-18"

Study condition terms

  • Endometrial Clear Cell Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Endometrial Dedifferentiated Carcinoma (protocolSection.conditionsModule.conditions)
  • Endometrial Endometrioid Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Endometrial Mixed Cell Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Endometrial Serous Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Endometrial Undifferentiated Carcinoma (protocolSection.conditionsModule.conditions)
  • Recurrent Endometrial Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Recurrent Endometrial Carcinoma (protocolSection.conditionsModule.conditions)
  • Recurrent Endometrial Clear Cell Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Recurrent Endometrial Dedifferentiated Carcinoma (protocolSection.conditionsModule.conditions)
  • Recurrent Endometrial Endometrioid Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Recurrent Endometrial Mixed Cell Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Recurrent Endometrial Serous Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Recurrent Endometrial Undifferentiated Carcinoma (protocolSection.conditionsModule.conditions)
  • Stage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8 (protocolSection.conditionsModule.conditions)
  • Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8 (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.